Luke Fostvedt
Overview
Explore the profile of Luke Fostvedt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fostvedt L, Zhou J, Kondic A, Androulakis I, Zhang T, Pryor M, et al.
J Pharmacokinet Pharmacodyn
. 2025 Jan;
52(1):14.
PMID: 39825146
No abstract available.
2.
Wang Y, Pei X, Niu T, Korth-Bradley J, Fostvedt L
CPT Pharmacometrics Syst Pharmacol
. 2024 Dec;
14(2):351-364.
PMID: 39652456
Fully Bayesian approaches are not commonly implemented for population pharmacokinetic (PK) modeling. In this paper, we evaluate the use of Stan with R and Torsten for population PK modeling of...
3.
Fostvedt L, Liu J, Wang X, Li Y, Johnson J, Wood L, et al.
Clin Pharmacol Drug Dev
. 2024 Aug;
13(10):1098-1107.
PMID: 39212958
Abrocitinib is a selective Janus kinase 1 inhibitor approved for the treatment of atopic dermatitis. It is metabolized primarily by cytochrome P450 (CYP) 2C19 (approximately 53%) and CYP2C9 (approximately 30%),...
4.
Wang Y, Fostvedt L, Wojciechowski J, Irby D, Nicholas T
CPT Pharmacometrics Syst Pharmacol
. 2024 Aug;
13(10):1615-1629.
PMID: 39086047
PoissonERM is an R package used to conduct exposure-response (ER) analysis on binary outcomes for establishing the relationship between exposure and the occurrence of adverse events (AE). While Poisson regression...
5.
Armstrong A, F Alexis A, Blauvelt A, Silverberg J, Feeney C, Levenberg M, et al.
Dermatol Ther (Heidelb)
. 2024 Jun;
14(7):1849-1861.
PMID: 38896380
Introduction: Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4...
6.
Wojciechowski J, Malhotra B, Wang X, Fostvedt L, Valdez H, Nicholas T
Br J Clin Pharmacol
. 2022 Mar;
88(8):3856-3871.
PMID: 35342978
Aims: Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate-to-severe atopic dermatitis. Herein we describe the time-course of drug-induced platelet reduction following abrocitinib administration, identify covariates...
7.
Wojciechowski J, Malhotra B, Wang X, Fostvedt L, Valdez H, Nicholas T
Clin Pharmacokinet
. 2022 Feb;
61(4):591.
PMID: 35178675
No abstract available.
8.
Wojciechowski J, Malhotra B, Wang X, Fostvedt L, Valdez H, Nicholas T
Clin Pharmacokinet
. 2022 Jan;
61(5):709-723.
PMID: 35061234
Background And Objective: Abrocitinib is a Janus kinase 1 inhibitor in development for the treatment of atopic dermatitis (AD). This work characterized orally administered abrocitinib population pharmacokinetics in healthy individuals,...
9.
Stypinski D, Fostvedt L, Lam J, Vaz A, Johnson T, Boerma J, et al.
J Clin Pharmacol
. 2020 May;
60(9):1254-1267.
PMID: 32441835
While an initial clinical absorption, distribution, metabolism, and excretion (ADME) study (Study 1; N = 6) with 100 mg/100 µCi [ C]lorlatinib, radiolabeled on the carbonyl carbon, confirmed that the...
10.
Rasmussen C, Smith M, Ito K, Sundararajan V, Magnusson M, Jonsson E, et al.
AAPS J
. 2018 Mar;
20(3):52.
PMID: 29549459
Every year, the pharmaceutical industry generates a large number of scientific reports related to drug research, development, and regulatory submissions. Many of these reports are created using text processing tools...